NRX Pharmaceuticals
NRXP
34 hedge funds and large institutions have $25.1M invested in NRX Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 12 closing their positions.
103% more capital invested
Capital invested by funds: $12.4M → $25.1M (+$12.7M)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
27% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $1.05M
1.1% more ownership
Funds ownership: 0.44% → 1.54% (+1.1%)
11% less funds holding
Funds holding: 38 → 34 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$20.4M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.55M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$2.04M |
| 4 |
Renaissance Technologies
New York
|
+$452K |
| 5 |
State Street
Boston,
Massachusetts
|
+$338K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$315K |
| 2 |
VF
Virtu Financial
New York
|
-$294K |
| 3 |
Jane Street
New York
|
-$257K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$157K |
| 5 |
Squarepoint
New York
|
-$141K |
NRXP Hedge Fund Activity: Q1 2022 in Review
34 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q1 2022, worth a combined $25.1M — up 103% from $12.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NRXP and 8 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $20.4M. The largest seller was Vanguard Group, cutting an estimated $315K.
- 34 institutional investors held NRX Pharmaceuticals (NRXP) as of Q1 2022, down from 38 in Q4 2021.
- Funds reported $25.1M of NRX Pharmaceuticals stock for Q1 2022, up 103% quarter-over-quarter.
- 8 funds opened new NRX Pharmaceuticals positions in Q1 2022 and 12 closed out, a net change of -4 holders.
- The largest NRX Pharmaceuticals buyer in Q1 2022 was Armistice Capital, an estimated $20.4M added.
- The largest NRX Pharmaceuticals seller in Q1 2022 was Vanguard Group, an estimated $315K sold.
Based on aggregated 13F filings for Q1 2022.